VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells
- 1 January 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (1) , 120-133
Abstract
Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF therapy in multiple experimental tumor models that differ in their glycolytic phenotypes to gain insights into optimal modulation of the metabolic features of this therapy. Prolonged treatments induced vascular regression and necrosis in tumor xenograft models, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic tumors. By PET imaging, prolonged treatments yielded an increase in both hypoxic and proliferative regions of tumors. A selection for highly glycolytic cells was noted and this metabolic shift was stable and associated with increased tumor aggressiveness and resistance to VEGF blockade in serially transplanted mice. Our results support the hypothesis that the highly glycolytic phenotype of tumor cells studied in xenograft models, either primary or secondary, is a cell-autonomous trait conferring resistance to VEGF blockade. The finding that metabolic traits of tumors can be selected by antiangiogenic therapy suggests insights into the evolutionary dynamics of tumor metabolism. Cancer Res; 75(1); 120–33. ©2014 AACR.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate DehydrogenaseCell Metabolism, 2013
- AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In VivoCell Metabolism, 2013
- Links between metabolism and cancerGenes & Development, 2012
- Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenograftsThe FEBS Journal, 2012
- The AMPK signalling pathway coordinates cell growth, autophagy and metabolismNature Cell Biology, 2011
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaProceedings of the National Academy of Sciences, 2011
- Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor CellsScience, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProceedings of the National Academy of Sciences, 2007
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002